US Patent

US7491725 — Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Composition of Matter · Assigned to Bristol Myers Squibb Co · Expires 2026-03-28 · 0y expired

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects processes for preparing compounds that are useful as kinase inhibitors, specifically protein tyrosine kinase and p38 kinase inhibitors.

USPTO Abstract

The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R 2 , R 3 , R 4 , and R 5 , are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.

Drugs covered by this patent

Patent Metadata

Patent number
US7491725
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-03-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.